Moonlake Immunotherapeutics (MLTX) Stock Price & Analysis
Moonlake Immunotherapeutics (MLTX) fell 1.11% to USD 17.8 as of June 10, 2026 at 11:16 UTC, according to Nexqual real-time market data.
MLTX last closed at USD 18; the session ranged USD 17.36–18.9 on volume of 961,456 shares. Market capitalization is $1.31B, with a 52-week range of USD 5.95–62.75 (NCM). Source: Nexqual, June 10, 2026 at 11:16 UTC.
Key Statistics (as of June 10, 2026 at 11:16 UTC)
| Price | USD 17.8 |
|---|---|
| Change | ▼ 1.11% (down) |
| Previous Close | USD 18 |
| Open | USD 18.29 |
| Day Range | USD 17.36 – 18.9 |
| 52-Week Range | USD 5.95 – 62.75 |
| Volume | 961,456 shares |
| Market Cap | $1.31B |
| Exchange | NCM |
Technical Analysis (MLTX)
Nexqual's technical model rates MLTX "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 11:16 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.39 (neutral) |
| vs SMA50 | Above (USD 17.72) |
| MACD | 0.21 (positive) |
Analyst Ratings (MLTX)
Wall Street analysts rate MLTX "Buy" based on 13 analysts, with a mean price target of USD 27.62 (range USD 6–46), per Nexqual as of June 10, 2026 at 11:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 27.62 |
| High Target | USD 46 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 11 / 2 / 2 |
Earnings (MLTX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.92 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.98 vs est -0.92 ▼ miss |
| 2025-12-31 | USD -0.92 vs est -0.94 ▲ beat |
| 2025-09-30 | USD -1.1 vs est -0.92 ▼ miss |
| 2025-06-30 | USD -0.87 vs est -0.76 ▼ miss |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Financials & Fundamentals (MLTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -77.85% |
| Debt / Equity | 39.68 |
| Current Ratio | 8.6 |
| Total Cash | $357.92M |
| Total Debt | $100.80M |
| Free Cash Flow | $-135.94M |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Financial Health Score (MLTX)
Nexqual rates Moonlake Immunotherapeutics's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $358M cash vs $101M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$224M |
| Efficiency | Critical — ROE -78%, ROA -36.7% |
Ownership (MLTX)
| Insider Ownership | +9.68% |
|---|---|
| Institutional Ownership | +87.92% |
| Shares Outstanding | 73.62M |
| Float | 39.62M |
| Short % of Float | +11.08% |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Leadership (MLTX)
Moonlake Immunotherapeutics is led by Jorge Santos da Silva (age 48), Co-Founder, Interim Chair of the Board & CEO, per Nexqual as of June 10, 2026 at 11:16 UTC.
| Co-Founder, Interim Chair of the Board & CEO | Jorge Santos da Silva (age 48) |
|---|---|
| Co-Founder & Chief Scientific Officer | Kristian Reich (age 59) |
| Chief Financial Officer | Matthias Bodenstedt (age 37) |
| Director of Investor Relations & External Communications | Carla Bretes |
| Associate Vice-President of Legal & Compliance | Joana Cortez |
Major Backers & Investors (MLTX)
Notable institutional backers of Moonlake Immunotherapeutics include BVF Inc., Deep Track Capital, Lp, Cormorant Asset Management, LP, according to Nexqual as of June 10, 2026 at 11:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 21.74% |
| Deep Track Capital, Lp | 8.71% |
| Cormorant Asset Management, LP | 6.09% |
| Janus Henderson Group PLC | 4.69% |
| Shaw D.E. & Co., Inc. | 3.25% |
| MPM Bioimpact LLC | 2.46% |
| Weiss Asset Management Lp | 2.32% |
| Logos Global Management LP | 2.04% |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
From Moonlake Immunotherapeutics's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property As of December 31, 2025, we have the exclusive license to a patent family directed to Il-17 Nanobodies, including SLK, and methods of making and using the same derived from International Patent Application PCT/EP2012/058313, published as WO 2012/156219, entitled "Amino Acid Sequences Directed Against IL-17A, IL-17F and/or IL17-A/F and Polypeptides Comprising the Same".
- In November 2025, we were granted a Type B meeting with the FDA to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application ("BLA") and in January 2026, we announced positive feedback from this interaction, confirming that we may establish substantial evidence of effectiveness ("SEE") without additional clinical trials in HS.
- The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
Partnerships
- The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement On April 29, 2021, we entered into a license agreement with MHKDG (the "License Agreement").
- Effective July 1, 2021, we entered into a contract manufacturing agreement with Richter Biologics with respect to the manufacture of SLK.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMVT | Immunovant, Inc. | USD 31.61 | ▲ 1.61% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| VERA | Vera Therapeutics, Inc. | USD 31.81 | ▼ 1.49% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:16 UTC. This page is informational and not investment advice.